GRIFOLS SA-ADR

GRFS is the ticker symbol for Grifols S.A., a global healthcare company specializing in plasma-derived medicines and transfusion medicine. U.S. investors typically access GRFS through its American Depositary Receipts (ADRs) listed on the Nasdaq. The ADRs represent shares of the Spanish parent company, and each ADR may correspond to a fraction of an ordinary share. For precise details on the ADR ratio and listing status, check the latest GRFS data on the page.

Grifols operates in the biotechnology and pharmaceutical industry, with a focus on plasma-derived therapies and diagnostic solutions. The company collects human plasma and transforms it into treatments for chronic and rare diseases, including immunodeficiencies and hemophilia. It also provides hospital pharmacy services and transfusion medicine products. This niche places GRFS within the broader healthcare sector, specifically in the plasma protein therapeutics market.

Recent performance for GRFS depends on current market conditions and company-specific news. As of the latest available data, the stock’s price and percentage changes are displayed on the page. For up-to-date performance, including daily, weekly, or year-to-date moves, refer to the live quote and chart on this page. These reflect the most recent trading activity and any after-hours changes.

Evaluating GRFS involves comparing its valuation multiples—such as price-to-earnings (P/E), price-to-sales (P/S), and enterprise value-to-EBITDA—against peers in the plasma therapeutics and broader healthcare sector. Analysts also consider growth prospects, margins, and debt levels. Because GRFS is based in Spain, currency fluctuations and ADR premiums may affect the valuation. For current ratios and comparisons, consult the valuation metrics provided on this page.

Before researching GRFS, understand that it is a Spanish company whose ADRs trade on Nasdaq, so factors like currency exchange rates and geopolitical risks may apply. The plasma therapeutics industry is capital-intensive and highly regulated. GRFS’s financial statements are reported in euros, which can complicate direct comparisons with U.S. peers. Additionally, the company has a complex corporate structure and significant debt. Review the latest GRFS data on this page for current financial and market information.

Grifols has historically paid dividends, but payout policies can change based on financial performance and strategic priorities. Whether GRFS currently pays a dividend, and the amount, should be confirmed via the latest data on this page. Dividend payments may be subject to Spanish withholding taxes for U.S. investors, and the ADR depositary may charge fees. Check the dividend section on this page for the most recent information.